Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Baseimmune logo — Pioneering the next generation of active immunotherapies for...

Baseimmune

Pioneering the next generation of active immunotherapies for chronic diseases

Founded 2019 United Kingdom London, United Kingdom 29 employees Series A Total: $13.19M Biotechnology, Health Care +1

General Information

Company Name Baseimmune
Founded Year 2019
Location United Kingdom London, United Kingdom +1
Employees 29
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series A
Social

Get notified when Baseimmune moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Baseimmune

Baseimmune is a UK-based company founded in 2019, marking its presence in the Biotechnology, Health Care, and Life Sciences industries. Emphasizing its slogan, "Pioneering the next generation of active immunotherapies for chronic diseases," the company operates in the specialized area of antigen discovery and vaccine development.

The recent successful closure of a £9.00M Series A investment on 01 February 2024 illustrates growing confidence in Baseimmune's innovative capabilities. Esteemed investors such as Hoxton Ventures, Beast Ventures, Creator Fund, IQ Capital, Maki.vc, and the MSD Global Health Innovation Fund participated in this funding round, highlighting significant support for the company's growth trajectory.

Future prospects for Baseimmune are bolstered by its strategic positioning in addressing chronic diseases via cutting-edge immunotherapies, a promising avenue within its field of operation. The firm remains a compelling consideration for investors interested in innovative healthcare solutions with long-term potential.

Taxonomy: Active Immunotherapies, Chronic Diseases, Antigen Discovery, Vaccine Development, Biotech Startup, Next Generation Vaccines, Discovery Phase, Immunology, Biotechnology Innovation, Healthtech Startup, Biomedical Research, Preventive Medicine, Pharmaceutical Research

Services & Products

design and development of novel immunotherapies
platform for bespoke antigen creation

Target Customers

patients with chronic diseases healthcare providers and professionals biotech and pharmaceutical companies

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series A £9.00M 6
Hoxton Ventures Beast Ventures Creator Fund IQ Capital Maki.vc MSD Global Health Innovation Fund
01 Feb 2024
Seed £3.50M 6
Cherry Ventures Hoxton Ventures Beast Ventures Creator Fund Maki.vc
Rockmount Seed Investments 		01 Nov 2021
Seed £690.00K 3
Creator Fund Maki.vc
Barinthus Biotherapeutics 		01 Apr 2021
Support Program Unknown 1
KQ Labs
01 Dec 2019

Latest News

View All
Bristol-based Empirical Ventures targets €11.6 million fund to lead early-stage deep science rounds — Eu-startups
Bristol-based Empirical Ventures targets €11.6 million fund to lead early-stage deep science rounds
Eu-startups Apr 04, 2024

Baseimmune Alternatives & Competitors

Baseimmune vs
Liberum Biotech
Liberum Biotech

The Protein Discovery Company

Seed
6 employees
Biotechnology, Manufacturing
Compare Baseimmune vs Liberum Biotech
Baseimmune vs
Collisionable
Collisionable

Experience the ultimate social platform for discovering and engaging with startups worldwide, sparki...

Pre Seed
2-10 employees
Finance, Social Media
Compare Baseimmune vs Collisionable
Baseimmune vs
LYNK Pharmaceuticals
LYNK Pharmaceuticals

Pioneering novel treatments for oncology, immunology, and inflammatory diseases since 2018.

Series C
11-50 employees
Biotechnology, Health Care
Compare Baseimmune vs LYNK Pharmaceuticals

FAQ About Baseimmune

Pioneering the next generation of active immunotherapies for chronic diseases
Baseimmune was founded in 2019.
Baseimmune is headquartered in London, United Kingdom.
Baseimmune operates in the following industries: Biotechnology, Health Care, Life Sciences.
Baseimmune has approximately 29 employees.
Baseimmune has completed 4 funding rounds, raising a total of $13.19M. The latest funding stage is Series A.
Baseimmune offers: design and development of novel immunotherapies, platform for bespoke antigen creation.
Top alternatives and competitors to Baseimmune include Liberum Biotech, Collisionable, LYNK Pharmaceuticals, Veritas In Silico Inc., INTONATION RESEARCH LABORATORIES PRIVATE LIMITED. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Baseimmune and Liberum Biotech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Baseimmune and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy